A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
Status:
Not yet recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
This will be a 12-month, multicenter, vehicle-controlled, double-masked, randomized Phase 3
study conducted at approximately 10 sites in the United States. All subjects enrolled will
have dry eye disease (DED). The study will consist of a Baseline (Day 1) visit as well as
visits at Day 14, Day 90, Day 180, Day 270, and Day 365 (Study Exit).